Highlands Oncology Group Physician Published in the British Journal of Haematology. Fayetteville, AR. March, 2014.
March 14, 2014 (Newswire.com) - Dr. J. Thaddeus Beck, of Highlands Oncology Group (HOG), has been published in the British Journal of Haematology for research on treatment options for mantle cell lymphoma.
Mantle cell lymphoma is a rare type of non Hodgkin lymphoma (NHL), according to the National Cancer Institute (NCI). About five-to-10 out of every 100 people diagnosed with NHL have mantle cell lymphoma. It mainly affects men 50 years old or older, according to the NCI.
The research focused on the effects different combinations of medications had for the treatment of mantle cell lymphoma.
Dr. Beck has been published in several different medical journals recently, including Current Medical Research & Opinion and Breast Cancer Research and Treatment, for research on treatment options for various forms of cancer.
The British Journal of Haematology is a peer-reviewed medical journal focusing on hematology and other blood-related topics, such as blood diseases and their treatment, according to the Wiley Online Library, an online collection of resources in the sciences and arts. It is published by Wiley-Blackwell on behalf of the British Society for Haematology.
Read the study here: http://onlinelibrary.wiley.com/doi/10.1111/bjh.12780/abstract
Highlands Oncology Group is a state-of-the-art facility, with a world-class team of specialists, that is committed to providing premier cancer treatment and to enhancing the quality of life of patients and their loved ones. Highlands Oncology group provides this in a friendly, comfortable environment conveniently located in Northwest Arkansas. Highlands offers the latest technology of diagnostic imaging and radiation therapies, on-site labs, a pharmacy and an infusion center. They also offer access to clinical trials, multidisciplinary clinics and support groups. Highlands Oncology Group is helping patients win the battle against cancer every day.
For more information visit www.HighlandsOncologyGroup.com.